Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TXG 
10X Genomics Inc (TXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: TXG (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 15.41% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio - | 1Y Target Price 16.31 |
Price to earnings Ratio - | 1Y Target Price 16.31 | ||
Volume (30-day avg) 3164473 | Beta 1.93 | 52 Weeks Range 9.27 - 37.86 | Updated Date 03/27/2025 |
52 Weeks Range 9.27 - 37.86 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.9% | Operating Margin (TTM) -30.2% |
Management Effectiveness
Return on Assets (TTM) -12.77% | Return on Equity (TTM) -25.17% |
Valuation
Trailing PE - | Forward PE 196.08 | Enterprise Value 860862636 | Price to Sales(TTM) 1.92 |
Enterprise Value 860862636 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 1.41 | Enterprise Value to EBITDA -40.69 | Shares Outstanding 108245000 | Shares Floating 106019797 |
Shares Outstanding 108245000 | Shares Floating 106019797 | ||
Percent Insiders 2.75 | Percent Institutions 96.93 |
Analyst Ratings
Rating 3.76 | Target Price 20.14 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 8 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
10X Genomics Inc
Company Overview
History and Background
10X Genomics was founded in 2012. It emerged to address limitations in biological analysis, particularly in genomics. The company's initial focus was on single-cell sequencing, and it has since expanded into spatial genomics and other areas.
Core Business Areas
- Instrument Sales: 10x Genomics sells instruments required to run their assays. These include the Chromium X, Chromium iX, and Chromium Controller.
- Consumables: Consumables form a major part of 10X Genomics' revenue stream. These are the reagents and microfluidic chips required to perform single-cell and spatial analyses.
- Service: 10X Genomics offers comprehensive customer service that includes installation, support and repair of instruments.
Leadership and Structure
Serge Saxonov is the CEO. The organizational structure includes research and development, sales, marketing, operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Chromium Single Cell Gene Expression: A widely adopted solution for single-cell RNA sequencing. This has a significant market share in the single-cell analysis space. Competitors include Bio-Rad and Illumina. Market share is estimated to be around 60% in the single-cell gene expression market, by revenue.
- Visium Spatial Gene Expression: Enables spatial transcriptomics, allowing researchers to map gene expression within tissue sections. Competitors include NanoString Technologies. Market share is smaller than single-cell but growing rapidly. Estimated to be 30% in the spatial genomics market.
- Xenium In Situ: In situ analysis of spatial genomics, provides a high resolution analysis for cell based reactions and analytics. Competitors include NanoString Technologies.
Market Dynamics
Industry Overview
The genomics and proteomics market is rapidly growing, driven by advancements in sequencing technologies, increasing applications in drug discovery, and personalized medicine. There's increasing demand for single-cell and spatial analysis.
Positioning
10X Genomics is a leading provider of single-cell and spatial genomics solutions. Its competitive advantage lies in its integrated solutions, ease of use, and comprehensive support. However, the high cost of its products can be a disadvantage.
Total Addressable Market (TAM)
The TAM for single-cell and spatial genomics is estimated to be $60 billion. 10X Genomics is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Leading technology in single-cell and spatial genomics
- Strong brand recognition
- High-quality integrated solutions
- Large installed base of instruments
Weaknesses
- High cost of consumables and instruments
- Dependence on a few key products
- Potential for intellectual property disputes
- Relatively concentrated customer base
Opportunities
- Expansion into new markets (e.g., drug discovery)
- Development of new applications for existing technologies
- Strategic partnerships
- Increased adoption of spatial genomics
Threats
- Competition from other genomics companies
- Price pressure from competitors
- Technological disruptions
- Economic downturns
Competitors and Market Share
Key Competitors
- ILMN
- NVTA
- PACB
- ONT.L
Competitive Landscape
10X Genomics competes with larger companies like Illumina in certain areas. It has an advantage in single-cell and spatial genomics due to its specialized expertise. However, its higher prices can be a disadvantage.
Major Acquisitions
ReadCoor
- Year: 2020
- Acquisition Price (USD millions): 350
- Strategic Rationale: Expanded its capabilities in spatial genomics.
Growth Trajectory and Initiatives
Historical Growth: 10X Genomics has experienced rapid revenue growth in its early years, driven by adoption of single-cell sequencing. Recent growth has slowed.
Future Projections: Analysts project continued revenue growth, driven by spatial genomics and new product launches. However, growth rates are expected to be lower than historical levels.
Recent Initiatives: Recent initiatives include the launch of new spatial genomics products and expansion of its commercial footprint.
Summary
10X Genomics is a leading player in the rapidly growing genomics market, particularly in single-cell and spatial analysis. The company's strong brand and innovative technology give it a competitive edge. However, high costs and increasing competition present challenges. It needs to manage its expenses and focus on product differentiation to maintain its growth trajectory.
Similar Companies
- ILMN
- NVTA
- PACB
- LIFE
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 10X Genomics Inc
Exchange NASDAQ | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2019-09-12 | Co-Founder, CEO & Director Dr. Serge Saxonov Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1306 | Website https://www.10xgenomics.com |
Full time employees 1306 | Website https://www.10xgenomics.com | ||
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.